362 related articles for article (PubMed ID: 8899084)
1. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Mee AS; Rowley JL
Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
[TBL] [Abstract][Full Text] [Related]
2. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
3. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
Hatlebakk JG; Berstad A
Aliment Pharmacol Ther; 1997 Apr; 11(2):365-72. PubMed ID: 9146777
[TBL] [Abstract][Full Text] [Related]
5. Esomeprazole: a review of its use in the management of acid-related disorders.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
Hatlebakk JG; Berstad A
Aliment Pharmacol Ther; 1997 Dec; 11(6):1093-9. PubMed ID: 9663835
[TBL] [Abstract][Full Text] [Related]
7. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Newton M; Burnham WR; Kamm MA
Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
[TBL] [Abstract][Full Text] [Related]
8. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Robinson M; Sahba B; Avner D; Jhala N; Greski-Rose PA; Jennings DE
Aliment Pharmacol Ther; 1995 Feb; 9(1):25-31. PubMed ID: 7766740
[TBL] [Abstract][Full Text] [Related]
9. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Richter JE; Campbell DR; Kahrilas PJ; Huang B; Fludas C
Arch Intern Med; 2000 Jun; 160(12):1803-9. PubMed ID: 10871974
[TBL] [Abstract][Full Text] [Related]
10. Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.
Jones R; Crouch SL
Aliment Pharmacol Ther; 1999 Mar; 13(3):413-9. PubMed ID: 10102976
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
Mulder CJ; Westerveld BD; Smit JM; Oudkerk Pool M; Otten MH; Tan TG; van Milligen de Wit AW; de Groot GH;
Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
[TBL] [Abstract][Full Text] [Related]
12. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
Sontag SJ; Schnell TG; Chejfec G; Kurucar C; Karpf J; Levine G
Aliment Pharmacol Ther; 1997 Feb; 11(1):147-56. PubMed ID: 9042987
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole for maintenance of remission of erosive oesophagitis.
Freston JW; Jackson RL; Huang B; Ballard ED
Drugs; 2002; 62(8):1173-84. PubMed ID: 12010078
[TBL] [Abstract][Full Text] [Related]
14. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
[TBL] [Abstract][Full Text] [Related]
15. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole: an update of its place in the management of acid-related disorders.
Matheson AJ; Jarvis B
Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Franco MT; Salvia G; Terrin G; Spadaro R; De Rosa I; Iula VD; Cucchiara S
Dig Liver Dis; 2000 Nov; 32(8):660-6. PubMed ID: 11142573
[TBL] [Abstract][Full Text] [Related]
18. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Gremse DA
Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
[TBL] [Abstract][Full Text] [Related]
20. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
Bardhan KD; Hawkey CJ; Long RG; Morgan AG; Wormsley KG; Moules IK; Brocklebank D
Aliment Pharmacol Ther; 1995 Apr; 9(2):145-51. PubMed ID: 7605854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
